Search for content, post, videos

Xellia Opens New Facility

Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, announced the opening of a new active pharmaceutical ingredients (API) R&D Center of Excellence in Oslo, Norway.

Xellia specializes in the manufacture of quality, fermented and difficult-to-manufacture APIs. The Company is also developing APIs based on chemical synthesis, which involves complex, strictly controlled chemical reactions, utilizing its innovative Route-of-Synthesis procedures.

The new 1,900m2 state-of-the-art facility replaces the R&D center at the former manufacturing site in Oslo.